Research Progress on Molecular Mechanism and Drug Prevention and Treatment of Gefitinib Hepatotoxicity
10.13748/j.cnki.issn1007-7693.20222016
- VernacularTitle:吉非替尼肝毒性的分子机制及药物防治研究进展
- Author:
YIN Xiaoting
1
,
2
;
LI Min
3
,
4
;
SHEN Jiduo
2
;
XU Erping
1
;
BAI Ming
1
;
LI Yucheng
1
Author Information
1. Henan University of traditional Chinese Medicine, Henan Collaborative Innovation Center for Research and Development on the Whole Industry Chain of Yu-Yao, Academy of Chinese Medical Sciences, Zhengzhou 450046, China
2. Henan University of traditional Chinese Medicine, Department of Pharmacy, Zhengzhou 450046, China
3. Department of Medical Oncology, Zhengzhou People'
4. s Hospital, Zhengzhou 450008, China
- Publication Type:Journal Article
- Keywords:
gefitinib;
hepatotoxicity;
molecular mechanism;
drug prevention and treatment
- From:
Chinese Journal of Modern Applied Pharmacy
2023;40(15):2155-2160
- CountryChina
- Language:Chinese
-
Abstract:
As the first marketed epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib plays an important role in the targeted therapy of malignant tumors such as non-small cell lung cancer, but this drug can cause serious adverse effects such as liver toxicity. If the reaction occurs, the drug must be stopped for liver protection treatment, which greatly affects the treatment process of cancer. However, the mechanism of gefitinib-induced hepatotoxicity is still unclear, and clinical treatment measures are very limited. This article aims to review the molecular mechanism of gefitinib-induced hepatotoxicity and the commonly used clinical therapeutic drugs, so as to provide scientific basis for clinical prevention and rational drug use.
